In 1988 and the National Cholesterol Education Program (NCEP) had just issued its first set of guidelines recommending regular cholesterol testing for all adults. Cholestech Corporation started that same year and just two years later received FDA clearance to market the Cholestech LDX® System. The Cholestech LDX brought the power of lab-quality results to the point-of-care setting, greatly facilitating NCEP compliance and easing the operational logistics of regular lipid and liver enzymes testing for both healthcare professionals and patients.

Over the years the Cholestech LDX has continued to evolve by adding new tests to improve the convenience of cardiovascular and diabetes testing. The test menu has grown to include tests such as ALT and AST for liver monitoring, and hs-CRP, an emerging marker for inflammation. And the Cholestech LDX lipid profile and glucose test is perfectly suited to assist in identifying those at risk of metabolic syndrome - a precursor to coronary heart disease and type 2 diabetes.